MAX-ing out MYC: a novel small molecule inhibitor against MYC-dependent tumors.

Abstract

The Myc oncogene features prominently in human cancers, being overexpressed or activated in more than 70% of malignancies (1). It is a basic helix-loop-helix (bHLH) transcription factor that lies at the crossroads of many growth-promoting signal transduction and bioenergetic pathways (2). Genetic studies in animal models have revealed that suppression of… (More)
DOI: 10.1093/jnci/dju365

Topics

Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.